FDA Approvals in Oncology: January-March 2025
In the first quarter of 2025, the FDA issued 13 approvals for oncology treatments, covering nine types of cancer...
Category: Policy
In the first quarter of 2025, the FDA issued 13 approvals for oncology treatments, covering nine types of cancer...
Natalie Snider-Hoy, a PhD candidate at Wayne State University, attended AACR Early-career Hill Day 2025 to advocate for sustained...
In the final three months of 2024, the FDA issued 15 approvals in oncology, including several therapies that are...
Ten-year-old Michael Methner told his story about his experience being diagnosed with optic nerve glioma at the Rally for...
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
Expanding clinical trial eligibility requirements can help increase participation and more accurately show how treatments work in a real-world...
Highlights from a workshop and journal article that shared key considerations for including overall survival as an endpoint in...
The FDA issued 18 oncology-related approvals in Q2 2024 including two first-in-class drugs and a bispecific T-cell engager for...
Dr. Edward Cliff presented a poster on the clinical benefit of cancer drugs granted accelerated approval.
The FDA issued 14 oncology approvals this quarter, including the first tumor-infiltrating lymphocyte therapy.